Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy

BACKGROUND: A combination of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard first-line therapy for diffuse large B cell lymphoma (DLBCL), the most common aggressive lymphoma in adults. One of the major adverse effects of this regimen is vincristine...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatzl, Stefan, Posch, Florian, Rezai, Arwin, Gornicec, Maximilian, Beham-Schmid, Christine, Magnes, Theresa, Wangner, Sandro, Deutsch, Alexander, Greinix, Hildegard, Uhl, Barbara, Prochazka, Katharina T., Egle, Alexander, Greil, Richard, Melchardt, Thomas, Linkesch, Werner, Schulz, Eduard, Neumeister, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295169/
https://www.ncbi.nlm.nih.gov/pubmed/33625586
http://dx.doi.org/10.1007/s00520-021-06059-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295169/
https://www.ncbi.nlm.nih.gov/pubmed/33625586
http://dx.doi.org/10.1007/s00520-021-06059-2

Ejemplares similares